Athens, Greece

Violetta Constantinou-Kokotou

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.8

ph-index = 1


Company Filing History:


Years Active: 2010-2014

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Violetta Constantinou-Kokotou: A Trailblazer in Phospholipase Inhibition

Introduction

Violetta Constantinou-Kokotou, an esteemed inventor based in Athens, Greece, has made significant contributions to the field of biochemistry, particularly in the area of phospholipase inhibition. With a total of four patents to her name, her innovative research paves the way for new therapeutic approaches.

Latest Patents

Violetta's latest patents focus on novel methods and compounds for inhibiting human secreted phospholipase A2. One such patent details amides that act as inhibitors, where compounds can be processed by contacting phospholipase A2 with a specific structure that includes various chemical substituents. Another noteworthy patent introduces 2-oxoamide inhibitors based on dipeptides and pseudopeptides. This series has shown potential in selectively inhibiting GIVA cPLA2 and GVIA iPLA2, demonstrating significant effects on arachidonic acid release from RAW 264.7 macrophages.

Career Highlights

Violetta Constantinou-Kokotou currently serves as a researcher at the University of California. Her academic pursuits and inventive work have garnered her a reputation as a prominent figure in her field, especially due to her innovative approaches to understanding phospholipase activity.

Collaborations

Throughout her career, Violetta has collaborated with distinguished colleagues, including Edward A. Dennis and George Kokotos. These collaborations have fostered a productive environment for research and development, enabling her to enhance her inventions and innovate further in the biochemistry domain.

Conclusion

Violetta Constantinou-Kokotou stands out as a leading inventor, contributing significantly to pharmaceutical chemistry through her patents and collaborative efforts. Her ongoing research continues to influence the landscape of inhibitors for phospholipase A2, underscoring her invaluable role in advancing scientific knowledge and therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…